Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on

Verbeke, Caroline; Häberle, Lena; Lenggenhager, Daniela; Esposito, Irene

doi:10.1016/j.pan.2018.04.010

Citations

Citation copied

Verbeke, C., Häberle, L., Lenggenhager, D., & Esposito, I. (2018). Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. Pancreatology, 18(5), 467–476. https://doi.org/10.1016/j.pan.2018.04.010

Abstract

Neoadjuvant treatment has increasingly become an integral part of the multimodal management of patients with pancreatic cancer. In patients who are able to undergo surgery following preoperative therapy, tumour regression grading remains the diagnostic gold standard for the histomorphological assessment of the effect of neoadjuvant treatment. In recent years, however, there has been growing concern about inherent flaws of tumour regression grading systems as well as their imprecise and impractical criteria that result in divergence of